HealthyPhase 1NCT02170896
Bioavailability of BIBR 963 ZW After 50 mg of BIBR 1048 MS With and Without of Pantoprazole in Healthy Subjects
A Phase 1 study testing BIBR 1048 MS Capsule A, BIBR 1048 MS Capsule B and BIBR 1048 MS Capsule C in people with Healthy, run by Boehringer Ingelheim.
Trial summary
To assess the amount of BIBR 953 ZW in urine of 50 mg of BIBR 1048 bid over three days each administered as four experimental capsule formulations relative to drinking solution with and without coadministration of 40 mg pantoprazole. Read more about this study
- Who is it for?
- Ages 18 to 55 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- BIBR 1048 MS Capsule A, BIBR 1048 MS Capsule B and BIBR 1048 MS Capsule C
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- No sites listed yet
- Study dates
- Oct 2001to Dec 2001
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy male subjects as determined by results of screening
- Signed written informed consent in accordance with GCP (Good Clinical Practice) and local legislation
- Age >= 18 and <= 55 years
- Body Mass Index (BMI) >= 18.5 and <= 29.9 kg/m²
Who cannot join
- Any finding at the medical examination (including blood pressure, pulse rate and ECG (electrocardiogram)) deviation from normal and of clinical relevance
- History of or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders
- History of relevant orthostatic hypotension, fainting spells and blackouts
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
Show all 21Show fewer
- History of any bleeding disorder including prolonged or habitual bleeding
- History of other hematologic disease
- History of cerebral bleeding (e.g. after a car accident)
- History of commotio cerebri
- Intake of drug with a long half-life (> 24 hours) within 1 month prior to administration
- Use of any drugs that might influence the results of the trial within 10 days prior to administration or during the trial
- Participation in another trial with an investigational drug within 2 months prior to administration or during trial
- Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from smoking on study days
- Alcohol abuse (> 60g/day)
- Drug abuse
- Blood donation within 1 month prior to administration or during the trial
- Excessive physical activities within 5 days prior to administration or during the trial
- Any laboratory value outside the clinically accepted reference range
- History of any familial bleeding disorder
- Thrombocytes < 150000/µl
About this study
Official title: Bioavailability of BIBR 953 ZW After 50 mg of BIBR 1048 MS (Oral Prodrug of BIBR 953) in 4 Experimental Formulations Relative to Drinking Solution of BIBR 1048 MS, Each Treatment Given Bid Over 3 Days, in Healthy Subjects. Intraindividual Comparison (5-way Crossover), Randomised, Open. For Each of the 5 Treatments, Investigation of 2 Conditions: With and Without Pantoprazole (Intraindividual, Open Comparison).
To assess the amount of BIBR 953 ZW in urine of 50 mg of BIBR 1048 bid over three days each administered as four experimental capsule formulations relative to drinking solution with and without coadministration of 40 mg pantoprazole.
- Conditions
- Healthy
- Being tested
- BIBR 1048 MS Capsule A, BIBR 1048 MS Capsule B, BIBR 1048 MS Capsule C, BIBR 1048 MS Capsule D, BIBR 1048 MS tartaric acid solution
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BIBR 1048 MS Capsule ADrug
BIBR 1048 MS Capsule BDrug
BIBR 1048 MS Capsule CDrug
BIBR 1048 MS Capsule DDrug
BIBR 1048 MS tartaric acid solutionDrug
PantoprazoleDrug
| Study group | Role | What they receive |
|---|---|---|
| Period 1: BIBR1048 MS Capsule A+Pantoprazole | Experimental | Not described Receives: Drug: BIBR 1048 MS Capsule A; Drug: Pantoprazole |
| Period 1: BIBR1048 MS Capsule B+Pantoprazole | Experimental | Not described Receives: Drug: BIBR 1048 MS Capsule B; Drug: Pantoprazole |
| Period 1: BIBR1048 MS Capsule C+Pantoprazole | Experimental | Not described Receives: Drug: BIBR 1048 MS Capsule C; Drug: Pantoprazole |
| Period 1: BIBR1048 MS Capsule D+Pantoprazole | Experimental | Not described Receives: Drug: BIBR 1048 MS Capsule D; Drug: Pantoprazole |
| Period 1: BIBR1048 MS solution+Pantoprazole | Active comparator | Not described Receives: Drug: BIBR 1048 MS tartaric acid solution; Drug: Pantoprazole |
| Period 2: BIBR1048 MS Capsule C | Experimental | Not described Receives: Drug: BIBR 1048 MS Capsule C |
| Period 2: BIBR1048 MS Capsule D | Experimental | Not described Receives: Drug: BIBR 1048 MS Capsule D |
| Period 2: BIBR1048 MS solution | Active comparator | Not described Receives: Drug: BIBR 1048 MS tartaric acid solution |
What is being measured
The primary outcome is the main question the study is designed to answer.
Ae 0-12h: amount of drug (total BIBR 953 ZW) excreted into urine during all individual dosing intervals
Measured: up to 3 days after each administration
Area under the concentration time course at steady state (AUCss)
Measured: 0.5, 1, 1.5, 2, 4, 6, 8 and 12 hours after study drug administration on day 3 of period 2
Secondary outcomes (3)
Occurence of adverse events
Measured: up to 40 days
Maximum plasma concentration at steady state (Cmax,ss)
Measured: 0.5, 1, 1.5, 2, 4, 6, 8 and 12 hours after study drug administration on day 3 of period 2
Time at which maximum plasma concentration occurs after dosing during steady state (tmax,ss)
Measured: 0.5, 1, 1.5, 2, 4, 6, 8 and 12 hours after study drug administration on day 3 of period 2
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jun 2014 (estimated)
- Study startOct 2001
- Primary completionDec 2001
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by Boehringer IngelheimThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02170896
- Sponsor's protocol ID
- 1160.31
- Status last verified
- Jun 2014
- First submitted
- 20 Jun 2014
- Last updated
- 23 Jun 2014
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jun 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bioavailability of BIBR 953 ZW After 50 mg of BIBR 1048 MS (Oral Prodrug of BIBR 953) in 4 Experimental Formulations Relative to Drinking Solution of BIBR 1048 MS, Each Treatment Given Bid Over 3 Days, in Healthy Subjects. Intraindividual Comparison (5-way Crossover), Randomised, Open. For Each of the 5 Treatments, Investigation of 2 Conditions: With and Without Pantoprazole (Intraindividual, Open Comparison).
- ClinicalTrials.gov ID
- NCT02170896
- Acronym / sponsor ID
- 1160.31
- Conditions
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- Boehringer IngelheimIndustry (pharma, biotech, devices)
- Study start
- Oct 2001
- Primary completion
- Dec 2001 (actual)
- First posted
- 23 Jun 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To assess the amount of BIBR 953 ZW in urine of 50 mg of BIBR 1048 bid over three days each administered as four experimental capsule formulations relative to drinking solution with and without coadministration of 40 mg pantoprazole.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 8
| Arm | Type | Receives |
|---|---|---|
| Period 1: BIBR1048 MS Capsule A+Pantoprazole | Experimental | Drug: BIBR 1048 MS Capsule A, Drug: Pantoprazole |
| Period 1: BIBR1048 MS Capsule B+Pantoprazole | Experimental | Drug: BIBR 1048 MS Capsule B, Drug: Pantoprazole |
| Period 1: BIBR1048 MS Capsule C+Pantoprazole | Experimental | Drug: BIBR 1048 MS Capsule C, Drug: Pantoprazole |
| Period 1: BIBR1048 MS Capsule D+Pantoprazole | Experimental | Drug: BIBR 1048 MS Capsule D, Drug: Pantoprazole |
| Period 1: BIBR1048 MS solution+Pantoprazole | Active comparator | Drug: BIBR 1048 MS tartaric acid solution, Drug: Pantoprazole |
| Period 2: BIBR1048 MS Capsule C | Experimental | Drug: BIBR 1048 MS Capsule C |
| Period 2: BIBR1048 MS Capsule D | Experimental | Drug: BIBR 1048 MS Capsule D |
| Period 2: BIBR1048 MS solution | Active comparator | Drug: BIBR 1048 MS tartaric acid solution |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Healthy male subjects as determined by results of screening
- Signed written informed consent in accordance with GCP (Good Clinical Practice) and local legislation
- Age >= 18 and <= 55 years
- Body Mass Index (BMI) >= 18.5 and <= 29.9 kg/m²
Key exclusion criteria (21 listed)
- Any finding at the medical examination (including blood pressure, pulse rate and ECG (electrocardiogram)) deviation from normal and of clinical relevance
- History of or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders
- History of relevant orthostatic hypotension, fainting spells and blackouts
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders
- Chronic or relevant acute infections
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BIBR 1048 MS Capsule A | Drug | Period 1: BIBR1048 MS Capsule A+Pantoprazole |
| BIBR 1048 MS Capsule B | Drug | Period 1: BIBR1048 MS Capsule B+Pantoprazole |
| BIBR 1048 MS Capsule C | Drug | Period 1: BIBR1048 MS Capsule C+Pantoprazole, Period 2: BIBR1048 MS Capsule C |
| BIBR 1048 MS Capsule D | Drug | Period 1: BIBR1048 MS Capsule D+Pantoprazole, Period 2: BIBR1048 MS Capsule D |
| BIBR 1048 MS tartaric acid solution | Drug | Period 1: BIBR1048 MS solution+Pantoprazole, Period 2: BIBR1048 MS solution |
| Pantoprazole | Drug | Period 1: BIBR1048 MS Capsule A+Pantoprazole, Period 1: BIBR1048 MS Capsule B+Pantoprazole, Period 1: BIBR1048 MS Capsule C+Pantoprazole, Period 1: BIBR1048 MS Capsule D+Pantoprazole, Period 1: BIBR1048 MS solution+Pantoprazole |
Primary outcome
Ae 0-12h: amount of drug (total BIBR 953 ZW) excreted into urine during all individual dosing intervals
Time frame: up to 3 days after each administration
Area under the concentration time course at steady state (AUCss)
Time frame: 0.5, 1, 1.5, 2, 4, 6, 8 and 12 hours after study drug administration on day 3 of period 2
3 secondary outcomes
Occurence of adverse events
Time frame: up to 40 days
Maximum plasma concentration at steady state (Cmax,ss)
Time frame: 0.5, 1, 1.5, 2, 4, 6, 8 and 12 hours after study drug administration on day 3 of period 2
Time at which maximum plasma concentration occurs after dosing during steady state (tmax,ss)
Time frame: 0.5, 1, 1.5, 2, 4, 6, 8 and 12 hours after study drug administration on day 3 of period 2
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jun 2014.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing BIBR 1048 MS Capsule A, BIBR 1048 MS Capsule B and BIBR 1048 MS Capsule C in people with Healthy, run by Boehringer Ingelheim.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Jun 2014. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Ae 0-12h: amount of drug (total BIBR 953 ZW) excreted into urine during all individual dosing intervals (time frame: up to 3 days after each administration). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jun 2014.